Last reviewed · How we verify

Liposomal Bupivacaine

Wake Forest University Health Sciences · FDA-approved active Small molecule

Liposomal Bupivacaine is a Local anesthetic Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Infiltration anesthesia and nerve block in surgical procedures, Postoperative analgesia. Also known as: Exparel, With Re-dosing, EXPAREL, Bupivacaine Liposome Injectable Suspension.

Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged numbing by slowly releasing bupivacaine at the injection site.

Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged nerve blockade by slowly releasing bupivacaine at the injection site. Used for Local anesthesia for infiltration, nerve block, and epidural anesthesia, Postoperative analgesia and pain management.

At a glance

Generic nameLiposomal Bupivacaine
Also known asExparel, With Re-dosing, EXPAREL, Bupivacaine Liposome Injectable Suspension, there is not another intervention involved. Please explain to me what you are referring to.
SponsorWake Forest University Health Sciences
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine blocks sodium channels in nerve cell membranes, preventing action potential propagation and thus pain signal transmission. By encapsulating bupivacaine in liposomes, the formulation achieves extended release over 72 hours or longer, providing sustained local anesthesia compared to conventional bupivacaine which has a shorter duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Liposomal Bupivacaine

What is Liposomal Bupivacaine?

Liposomal Bupivacaine is a Local anesthetic drug developed by Wake Forest University Health Sciences, indicated for Infiltration anesthesia and nerve block in surgical procedures, Postoperative analgesia.

How does Liposomal Bupivacaine work?

Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged numbing by slowly releasing bupivacaine at the injection site.

What is Liposomal Bupivacaine used for?

Liposomal Bupivacaine is indicated for Infiltration anesthesia and nerve block in surgical procedures, Postoperative analgesia.

Who makes Liposomal Bupivacaine?

Liposomal Bupivacaine is developed and marketed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

Is Liposomal Bupivacaine also known as anything else?

Liposomal Bupivacaine is also known as Exparel, With Re-dosing, EXPAREL, Bupivacaine Liposome Injectable Suspension, there is not another intervention involved. Please explain to me what you are referring to..

What drug class is Liposomal Bupivacaine in?

Liposomal Bupivacaine belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Liposomal Bupivacaine in?

Liposomal Bupivacaine is FDA-approved (marketed).

What are the side effects of Liposomal Bupivacaine?

Common side effects of Liposomal Bupivacaine include Injection site reactions, Transient neurological symptoms, Hypotension, Bradycardia.

What does Liposomal Bupivacaine target?

Liposomal Bupivacaine targets Voltage-gated sodium channels and is a Local anesthetic.

Related